ReviewClinical lymphoma, myeloma & leukemia2026

SOHO State of the Art Updates and Next Questions | Choosing the Best Frontline BCR::ABL1 Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia-How to Define the Treatment Value?

Fadi G Haddad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.